Hyemin Yang Pomerantz

Hyemin Pomerantz practices at Vivaskin Dermatology And Aesthetics in Wellesley, Massachusetts.

Hyemin Pomerantz's NPI, 1346506763, was assigned on April 10, 2012. Hyemin Pomerantz graduated from Harvard Medical School in 2012. Hyemin Pomerantz holds Massachusetts license 283097.

Hyemin Pomerantz's primary practice is Vivaskin Dermatology and Aesthetics, at 70 Hastings St, Wellesley, MA 02481-5439. The practice phone is (781) 261-0085.

Hyemin Pomerantz's primary practice is Vivaskin Dermatology And Aesthetics in Wellesley, Massachusetts. Hyemin Pomerantz is also affiliated with Beth Israel Deaconess Medical Center. The medical group on file is VivaSkin Dermatology and Aesthetics. Dmand AI also links Hyemin Pomerantz to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Hyemin Pomerantz practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Hyemin Pomerantz's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Hyemin Pomerantz is licensed in Massachusetts.

CMS data shows 912 Medicare services from Hyemin Pomerantz across 13 procedure codes in 2024, for 178 Medicare patients. Medicare paid $56,498 for them. Every service was in an office.

CMS counts 178 Medicare patients who saw Hyemin Pomerantz in 2024. The largest group is 65 to 74, with 89 patients. 73% of them have high cholesterol, and 63% have high blood pressure. 10% are also on Medicaid. Their average risk score is 0.99, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Hyemin Pomerantz's median patient age at 55, with 60% women.

In 2024, Hyemin Pomerantz wrote 413 Medicare Part D claims for 172 patients. 82% of them were for generic drugs. CMS names the drug for 291 of them, across 11 drugs with 11 or more claims each, at $120,390 in total drug cost. In 2023, CMS named 579 claims across 24 drugs.

Hyemin Pomerantz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 514 procedures of removal of skin lesions by Hyemin Pomerantz, more than 87% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Hyemin Pomerantz, published from 2016 to 2024. 2020 was the busiest year, with 5. The most frequent topics are Port-Wine Stain, Fluorouracil and Keratosis, Actinic. Hyemin Pomerantz has published most often in J Am Acad Dermatol. Hyemin Pomerantz's most frequent co-authors are Margo H. Lederhandler, Martin A. Weinstock, MD, PhD and Roy G. Geronemus, MD.

CMS Open Payments shows 276 general payments to Hyemin Pomerantz from 22 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 96% of the total. Abbvie Inc. paid the most, $2,108.

Hyemin Pomerantz graduated from Harvard Medical School in 2012.